NDAORALGRANULESPriority Review
Approved
Apr 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
1
Mechanism of Action
(including F508del-CFTR) to increase the amount of CFTR protein delivered to the cell surface compared to either molecule alone. Ivacaftor potentiates the channel open probability (or gating) of the CFTR protein at the cell surface. The combined effect of elexacaftor, tezacaftor and ivacaftor is…
Clinical Trials (1)
A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis
Started Jan 2017
225 enrolled
Cystic Fibrosis
Loss of Exclusivity
LOE Date
Jul 17, 2038
150 months away
Patent Expiry
Jul 17, 2038
Exclusivity Expiry
Dec 20, 2031